BMS-986523
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 01, 2025
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
(clinicaltrials.gov)
- P1/2 | N=252 | Not yet recruiting | Sponsor: Bristol-Myers Squibb
Monotherapy • New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1